VivoSeq
Oncology

Solid Tumor

149

Pipeline Programs↗

100

Active Trials↗

78

Companies Involved↗

Solid Tumor is a highly competitive landscape with 149 programs across 78 companies. The most active players are BeOne Medicines, Beijing Biostar Pharmaceuticals Co., Ltd., Astellas. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

79/100

Pipeline Velocity

58/100

Mech. Concentration

6/100

Completion Rate

78/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

BeOne Medicines

10 programs

Phase 1B

Beijing Biostar Pharmaceuticals Co., Ltd.

5 programs

Phase 1Astellas logo

Astellas

4 programs

Phase 1Johnson & Johnson logo

Johnson & Johnson

3 programs

Phase 1EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.

2 programs

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

82%

Small molecule

106 of 130 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody1512%Protein / enzyme65%Cell therapy22%Antibody–drug conjugate1<1%

Small molecule leads; the ring shows all 130 classified programs, each share of the total. Modality classified for 79% of 172 pipeline programs.

Analysis

Trial Status

154

clinical trials

Recruiting69 · 45%
Completed39 · 25%
Active, not recruiting18 · 12%
Not yet recruiting12 · 8%
Terminated7 · 5%
Unknown status4 · 3%
Other5 · 3%

Clinical Trials

Trial Activity

154 trials

HRYZ-T101 Injection for HPV18 Positive Solid Tumor
Recruiting·HHRYZ Biotech Co.·Phase 1·NCT05952947·32 enrolled
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor
Recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd. logoSuzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1·NCT07275242·107 enrolled
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
Recruiting·LLG Chem·Phase 1·NCT06332755·76 enrolled
Imatinib and Trametinib for KRAS-mutated Solid Tumor
Recruiting·—·Phase 1·NCT06962254·10 enrolled
Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion
Recruiting·SSamsung Medical Center·Phase 2·NCT06383884·30 enrolled
PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor
Recruiting·—·Phase 1·NCT06883149·25 enrolled
A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination With Anticancer Agents in Patients With Advanced Solid Tumors
Recruiting·BBeOne Medicines·Phase 1·NCT06589596·525 enrolled
PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced/Metastatic Solid Tumors That Are MTAP Deficient
Recruiting·AstraZeneca logoAstraZeneca·Preclinical·NCT06130553·334 enrolled
The Intersection of Oncology Care and Worker Well-Being
Recruiting·UUniversity of Colorado, Denver·N/A·NCT05250284·400 enrolled
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Recruiting·BeiGene logoBeiGene·Phase 1·NCT06120283·399 enrolled
A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications
Recruiting·SSynthekine·Preclinical·NCT05098132·364 enrolled
An Open, Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Efficacy of ICP-B208 in Participants of Advanced Solid Tumor Trials
Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Preclinical·NCT07617493·539 enrolled
A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT06997029·234 enrolled
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors
Recruiting·BBeOne Medicines·Phase 1·NCT07226349·105 enrolled
A Single-Arm, Multi-Center, Open-Label, Phase 2 Study to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody, as Monotherapy in Patients With Previously-Treated Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
Recruiting·BeiGene logoBeiGene·Phase 2·NCT03736889·200 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)